Table 3.
Susceptibility of WT and diclofenac reduced susceptibility (DcRS) mutants to NSAIDs
| Drug gradient plates (mg/ml)a | ||||||
|---|---|---|---|---|---|---|
| Strain | Ace (0→9) | Asa (0→3.6) | Ben (0→14.4) | Dc (0→0.5) | Ibu (0→4) | Sal (0→8) |
| SH1000 | 51 ± 4.2b | 24 ± 1.0 | 54 ± 3.2 | 13 ± 1.5 | 0 | 24 ± 2.1 |
| SC-1 | 51 ± 3.5 | 25 ± 0.6 | 52 ± 3.2 | 35 ± 5.4* | 28 ± 2.3* | 27 ± 0.6 |
| COL | 35 ± 1.2 | 22 ± 0.6 | 39 ± 3.2 | 23 ± 5.8 | 12 ± 1.5 | 31 ± 1.2 |
| SC-4 | 35 ± 0.6 | 21 ± 1.5 | 31 ± 1.5 | 35 ± 3.6* | 21 ± 0* | 30 ± 1.2 |
a Gradient plate technique; drug gradients prepared for acetaminophen (Ace), acetyl salicylic acid (Asa), benzoate (Ben), diclofenac (Dc), ibuprophen (Ibu), and sodium salicylate (Sal); concentration gradient provided in parentheses.
b Average growth into NSAID gradients and standard deviation provided in mm.
* Denotes statistically significant difference between WT and DcRS by Student's t-test (P < 0.05).